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Background: Several differences in basal cell carcinomas 
(BCCs) were found, according to the ethnic group; for 
example, pigmented BCCs was more common in Asian or 
Hispanic patients. However, there are few reports on the 
subclinical extension of the BCC in Asian patients. 
Objective:  The aim of this study was to evaluate the 
subclinical infiltration of the basal cell carcinoma in Asian 
patients. Methods: All patients with BCC who visited the 
department of dermatology at Korea University Ansan 
Hospital were treated with Mohs micrographic surgery. In 81 
patients, 83 tumors of BCC were completely eradicated by 
Mohs micrographic surgery (MMS) from April 2001 to August 
2008, and were reviewed in this study. Information recorded 
included the total margin and the number of stages of Mohs 
micrographic surgery, anatomic location, tumor size, 
presence of pigmentation, clinical type, and pathological 
subtype. We divided the clinical types into nodular, 
ulcerated, and pigmented, and the pathological types into 
nodular, micronodular, morpheaform, and adenoid. The 
BCC was of pigmented type if pigmentation covered more 
than 25% of the tumor, regardless of whether pigmentation 
was distinct, or if there was apparent pigmentation that 
covered more than 10% of the tumor. Results: The nose and 
cheek were the most common sites requiring more than one 
stage of surgery. In tumors smaller than 1 cm, 91.7% required 
only one stage of excision, compared with 60.6% in tumors 
larger than 1 cm. More than two Mohs stages were required 
in 25% of non-ulcerated BCCs and in 46.2% of ulcerated 
BCCs. Sixty eight percent of pigmented BCCs required only 
one stage of Mohs micrographic surgery. In cases of 
non-pigmented BCCs, only 45% required one Mohs stage. 
More than one Mohs stage was required in 19.2% of 
non-aggressive BCCs and in 42.9% of aggressive BCCs. 
Conclusion: Subclinical infiltration differed between the two 
groups according to the size of the BCC (1 cm threshold) and 
most of the BCCs were located in the head and neck area. 
Considering this result, indication for MMS can be extended 
for BCCs larger than 1 cm in Asian patients. Ulcerated BCCs 
required more Mohs stages than non-ulcerated BCCs. 
Pigmented BCCs might show lesser subclinical infiltration 
than non-pigmented BCCs. Aggressive pathological 
subtypes showed more subclinical infiltration than the 
non-aggressive types; however, after evaluation of the 
border that was excised with MMS, mixed histologic types 
were found to be more frequent than generally accepted. 
Therefore, we consider that, when planning surgery, derma-
tologists should not place too much confidence in the 
pathologic subtypes identified by biopsy. (Ann Dermatol 
23(3) 276∼281, 2011)
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common skin 
cancer, with increasing annual incidence in the Asians
1,2 
population. Although Mohs micrographic surgery (MMS) 
is the treatment of choice for BCC, the recurrence rate of 
BCC, even with MMS, is about 1∼2% for the primary 
BCC, and 4∼5% for the recurrent BCC, The cause of Subclinical Infiltration of Basal Cell Carcinoma in Asian Patients
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Table 1. Clinical and pathological tumor characteristics
Stage 1 (%) Stage  ＞2 (%) Odds ratio (95% CI) p-value
Sex 1.039 (0.143∼2.610) 0.935
  Male 22 (64.7) 12 (35.3)
  Female 30 (63.8) 17 (36.2)
Age 0.665 (0.164∼2.700) 0.566
  ＜50  5 (55.6)  4 (44.4)
  ≥50 47 (65.3) 25 (34.7)
Site 6.364 (0.772∼52.464) 0.054
  Not face 10 (90.9)  1 (9.1)
  Face 44 (61.6) 28 (38.4)
Size 7.163 (0.876∼58.593) 0.037
  ≤1 cm 11 (91.7)  1 (8.3)
 
  ＞1 cm 43 (60.6) 28 (39.4)
  ≤2 cm 43 (68.3) 20 (31.7) 1.759 (0.629∼4.919) 0.279
  ＞2 cm 11 (55)  9 (45)
Ulcer 2.571 (1.016∼6.507) 0.044
  No ulcer 33 (75) 11 (25)
  Ulcer 21 (53.8) 18 (46.2)
Pigmentation 0.391 0.143
  Non-pigmented  5 (45.5)  6 (54.5)
(0.108∼1.415)
  Pigmented 49 (68.1) 23 (31.9)
Pathologic subtype 0.216 (0.073∼0.638) 0.004
  Non-nodular  7 (36.8) 12 (63.2)
  Nodular 46 (73) 17 (27)
  Non-micronodular 30 (73.2) 11 (26.8) 2.134 (0.845∼5.389) 0.106
  Micronodular 23 (56.1) 18 (43.9)
  Non-morpheaform 36 (70.6) 15 (29.4) 1.976 (0.781∼5.005) 0.148
  Morpheaform 17 (54.8) 14 (45.2)
  Non-adenoid 39 (60.9) 25 (39.1) 0.446 (0.132∼1.509) 0.187
  Adenoid 14 (77.8)  4 (22.2)
Prognostic pathological subtype 3.150 (1.038∼9.555) 0.037
  Non-aggressive 21 (80.8)  5 (19.2)
  Aggressive type 32 (57.1) 24 (42.9)
recurrence may be the subclinical histologic extension of 
the tumor, beyond the clinical margin. It is the reason why 
we need to understand the subclinical infiltration of BCC, 
to increase the rate of complete excision by taking that 
pattern into account, along with several other factors affec-
ting incomplete excision; e.g. racial differences, tumor 
size, tumor site, and histologic subtype.
Several differences in BCCs were found, according to the 
ethnic group; for example, pigmented BCCs were more 
common in Asian or Hispanic patients
3,4. Until now, there 
have been few reports evaluating the subclinical margin of 
BCC in Asian patients. If there are differences in the 
subclinical extension and associated factors between Asi-
ans and Caucasians, there would be some differences in 
the recurrence of BCC, even with the same treatment. 
Therefore, we examined the clinical and histopathologic 
characteristics and the subclinical infiltration of 83 cases 
of BCC, completely excised by MMS at the Korea 
University hospital, from April 2001 to August 2008. 
MATERIALS AND METHODS
Patients
All patients with BCC who visited the department of 
dermatology at Korea University Ansan Hospital were 
treated with MMS, except for several patients who did not 
want surgical treatment. Of a total of 81 patients, 83 tumors 
of BCC that were completely eradicated by MMS from 
April 2001 to August 2008 were reviewed in this study. 
Methods 
The recorded information included age, sex, total margin 
and the number of stages of MMS, anatomic location, 
tumor size, presence of pigmentation, clinical type, and 
pathological subtype. We excised the tumor with a 2 mm 
margin from the tumor border, assessed using loupe mag-
nification. If a tumor was present on histologic exami-
nation, we excised additional skin with a 2 mm margin for 
each stage of MMS. Pathologic subtypes were categorized KW Ro, et al
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Fig. 1. Mohs stage according to the size of the basal cell carcinoma.
Fig. 2. Pathologic subtypes of basal cell carcinoma according to pigmentation. Nod: nodular, Mor: morpheaform, Mic: micronodular,
Ade: adenoid.
Table 2. Distribution of BCCs according to the Mohs stage
Stage 1 Stage 2≤ (%) Total
Scalp 7  0 (0) 7
Forehead 9  4 (30.8) 13
Periorbital 13  4 (23.5) 17
Nose 6  8 (57) 14
Ear 1  1 (50) 2
Postauricular 3  3 (50) 6
Cheek 8  8 (50) 16
Perioral 4  0 (0) 4
Chest 2  0 (0) 2
Arm 1  0 (0) 1
Hand 0  1 (100) 1
Total 52 29 83
BCCs: basal cell carcinomas.
into four subtypes, i.e. nodular, micronodular, morphea-
form, and adenoid. If one tumor had several pathological 
subtypes, all subtypes were counted separately, therefore 
all pathological subtypes were more than all tumor cases 
(i.e. 120 vs 83). Nodular and adenoid subtypes were 
grouped into non-aggressive types and the remaining two 
subtypes into aggressive types. The BCC was designated 
as pigmented if pigmentation covered more than 25% of 
the tumor, whether pigmentation was distinct, or if there 
was apparent pigmentation that covered more than 10% 
of the tumor. The number of stages with other variables 
mentioned above was preliminarily analyzed with the χ
2 
test. A p-value  ＜0.05 was considered statistically signi-
ficant. Statistical analyses were performed with SPSS soft-
ware version 12.0.
RESULTS
Clinical and pathological tumor characteristics are shown 
in Table 1. The average total margin and the number of 
stages required for complete tumor excision were 3.08 Subclinical Infiltration of Basal Cell Carcinoma in Asian Patients
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mm and 1.46 stages, respectively. Most of the tumors 
were located on the head and neck (79 cases, 95.2%). The 
nose and cheek were the most common sites requiring 
more than one stage surgery; however, considering the 
incidence, anatomic sites are not the factor affecting the 
number of MMS stages (Table 2). Most BCCs are 1∼2 cm 
in size. No statistical difference in the MMS stage was 
observed between the two groups (tumors ＜2 cm vs. 
tumors ≥2 cm). However, in tumors smaller than 1 cm, 
91.7% required only one stage of excision, compared 
with 60.6% of tumors larger than 1 cm (p＜0.037) (Fig. 
1A). More than one stage was required in 46.2% of 
ulcerated BCCs and in 25% of non-ulcerated BCCs, and 
there was a significant difference between the two groups 
(Table 1). Seventy two cases (86.7%) had pigmentation. 
No statistically significant difference in the number of sta-
ges was identified between pigmented and non-pigmented 
BCCs (Table 1). Pathological subtypes according to pig-
mentation are shown in Fig. 2. Nodular types were more 
than half of the pigmented BCCs; however, in non-pig-
mented BCCs, 47% were micronodular. Mixed types were 
60% of all cases. While 100% of non-aggressive types had 
clinically visible pigmentation, only 82.1% of aggressive 
types had pigmentation. 42.9% of aggressive pathologic 
types required more than 2 stages; however, only 19.2% 
of non-aggressive types required more than 2 stages. This 
difference was statistically significant (p＜0.037) (Table 1).
DISCUSSION
The purpose of the present study was to identify various 
factors associated with subclinical extension of the BCC in 
Asians.
In our study, 30.9% of patients with BCC were in their 
sixties, followed by seventies (27.2%), and fifties (18.5%). 
Female patients were more than male patients (58% vs. 
42%). Ninety five point two percent of BCCs developed 
on the head and neck, and only 4% were observed on the 
trunk and extremities. The nose and the cheek area were 
the most common sites requiring more than one stage 
surgery, followed by the periorbital area and forehead; 
however, considering the incidence, there was no 
statistically significant difference between these sites (i.e. 
nose 57%, cheek 50%, the periorbital area 24%, the 
forehead 31%).
Average stage and margin required for complete tumor 
excision were 1.46 and 3.04 mm, respectively. In 65% of 
patients, only 1 stage was needed. Kim et al.
5 reported 
that 55% of BCCs required only one stage. Leibovitch et 
al.
6 reported that the average number of stages for 
complete excision was 1.73. In reports presented by 
Smeets et al, only 25% of BCCs required only one stage
7. 
The reason for this difference between studies may be due 
to inconsistency in subjects’ selection for MMS, in tumor 
margins decided without a magnifying glass and in the 
amount of surgical margin excised at the first stage.
A number of reports have shown a higher rate of incom-
plete excision in tumors larger than 2 cm, compared to 
smaller ones; however, the difference was not statistically 
significant
8-10. In our study, the percentage of tumors 
requiring only one Mohs stage was 68% in tumors smaller 
than 2 cm and 55% in those larger than 2 cm; however, 
there was no statistically significant difference between 
the two groups. 
When a smaller size was considered (tumors ＜1 cm, 
tumors  ≥1 cm), the difference became significant (i.e. 
92% in tumors ＜1 cm, and 60% in tumors ≥1 cm). 
Several guidelines divide tumors into two main groups, 
i.e. the low risk and the high risk group (tumors ＜2 cm, 
tumors  ＞2 cm)
11-13. A tumor larger than 2 cm is an 
indication for MMS
14; however, according to some re-
ports, the subclinical extension or recurrence rate differed 
significantly between the two groups (tumors ＜1 cm, 
tumors ≥1 cm)
15. According to the National Comprehen-
sive Cancer Network (NCCN) guidelines, the high risk is 
defined by a tumor larger than 10 mm in the middle risk 
body area or 6 mm, in the high risk body area
16. 
Considering that most of the tumors in our study were 
found on the head and neck, which are middle or high 
risk body areas, our results showing significant diffe-
rences between the two groups of tumors (i.e. larger and 
smaller than 1 cm) corresponded to the NCCN guide-
lines. Therefore, in Asian patients, the indication for MMS 
could be extended for tumors larger than 1 cm, with 
consideration for several points. First, MMS has the 
advantage of complete evaluation of all margins. Second, 
margin positive rate was reported to be about 20%, if 
tumors were excised with a narrow margin of 1∼3 mm 
without checking free margin
17,18. Third, in our study, 
only 8% of tumors below 1cm required more than one 
excision.
In our study, 78% of basal cell carcinomas showed pig-
mentation, and this result was similar to those of other 
studies conducted in Asians
3,19. The percentage of pig-
mented BCC in our study was remarkably higher than that 
of Caucasians, showing only about 10% of BCC pig-
mentation
20,21. We studied the number of stages accor-
ding to the pigmentation of the BCC. The complete ex-
cision rate at one stage was 68.1% in pigmented BCC and 
45.5% in non-pigmented BCC. Hornblass and Stefano
22 
also reported that the complete excision rate was higher in 
pigmented BCC than in non-pigmented ones. Maloney et KW Ro, et al
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Fig. 3. (A, B) Basal cell carcinomas 
(BCCs) requiring only one Mohs 
stage for complete excision. They 
showed even pigmentation. (C, D) 
BCCs requiring more than one Mohs
stage for complete excision. They 
also showed even pigmentation; 
however, there was a bluish hue 
surrounding the tumors. 
al.
20 presented the same opinion in their reports, in which 
only one of 40 pigmented BCCs showed positive margins 
at one stage of MMS. In our study, the incidence of sub-
clinical extension was lower in pigmented BCC than in 
non-pigmented BCC, although there was no statistically 
significant difference between the two types. The clinical 
spectrum of pigmented BCCs was broad, ranging from 
BCCs showing speckled pigmentation in small areas to 
those showing total, even pigmentation. Evaluation of the 
subclinical extension of the BCC according to the indi-
vidual pattern of pigmentation, rather than simply grou-
ping into pigmented or non pigmented BCCs, would be 
preferable. We found some characteristics of pigmented 
BCCs. Thus, most pigmented BCCs showing even pigmen-
tation were excised completely at one stage (Fig. 3A). If 
there was a bluish hue surrounding the tumor, that tumor 
usually required more than one excision, despite having 
overall even pigmentation (Fig. 3B).
Fifty three point eight percent of BCCs with clinical ulcer 
and 75% of BCCs without clinical ulcer were completely 
excised at one stage, and the difference was statistically 
significant (Table 1). Therefore, it seems that ulceration 
could indicate the aggressiveness of BCCs.
The percentage of BCCs requiring only one MMS stage 
was 57.1% and 80.8% in the aggressive type and the 
non-aggressive type, respectively. This result was similar 
to those of several previous reports
15,16,23.
In our study, the BCCs with mixed pathologic type were 
60% of all cases. This percentage was higher than pre-
viously reported
1,24. This result may be attributed to the 
fact that we studied the border of the BCC after removal of 
the tumor with MMS. These lesions may have been 
diagnosed as one certain type of BCC with punch biopsy. 
This point supports the necessity of MMS for BCC.
In conclusion, in our study, the average stage and margin 
required for complete tumor excision were 1.46 and 3.04 
mm, respectively. Subclinical infiltration differed between 
the two groups according to the size of the BCC (smaller 
than 1 cm vs. larger than 1 cm) and most BCCs were 
located in the head and neck area. Considering this result, 
in Asian patients, the indication for MMS can be extended 
for BCCs larger than 1 cm. Ulcerated BCCs required more 
Mohs stages than non-ulcerated BCCs. Our results suggest 
that pigmented BCCs might show lesser subclinical infil-
tration than non-pigmented BCCs. However, as the degree 
of pigmentation varies largely it would be better to 
evaluate the pigmented BCCs according to the individual 
pattern of pigmentation, rather than simply considering 
the existence of pigmentation. The aggressive pathologic 
subtypes show more subclinical infiltration than the non- 
aggressive types; however, after evaluation of the border 
that was excised with MMS, mixed histologic types were 
found to be more frequent than generally accepted. There-
fore, when planning surgery, dermatologists should not Subclinical Infiltration of Basal Cell Carcinoma in Asian Patients
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place too much confidence in the pathologic subtypes 
identified by biopsy.
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